The unpredictability of the pharmaceutical market continued in the first quarter of 2025 with geopolitics and uncertainty keeping pharma players of all sizes under pressure. To help you stay on top of all the changes, our latest quarterly report provides analysis of the highlights – and lowlights – of the opening three months of the year.
From the impact of FDA cuts and tariff uncertainties to the latest M&A deals and IPO activities, our expert analysis and data-driven insights that will help you make informed decisions in these turbulent times.
Check out the report to receive:
- Detailed examination of Q1 2025 M&A activity: Including major deals and emerging trends.
- IPO and VC Trends: Insights into the latest IPOs and venture capital financings, highlighting key challenges and opportunities.
- Expert Commentary: Evaluate’s perspectives on the economic and regulatory factors shaping the biopharma landscape.
